No Data
Express News | Zhejiang Conba Pharmaceutical: Moschus Invigorating Pill has been approved for an extended protection period for national traditional Chinese medicine.
Zhejiang Conba Pharmaceutical (600572): Short-term performance under pressure, expecting a recovery in the second half of the year.
Event: The company disclosed its 2024 interim report, achieving revenue of 3.448 billion yuan, a year-on-year decrease of 8.40%; net income attributable to equity holders of 0.382 billion yuan, a year-on-year decrease of 25.95%; non-GAAP net income attributable to equity holders of 0.336 billion yuan, year-on-year.
Zhejiang Conba Pharmaceutical (600572): The impact of a high base is gradually being digested. Bullish on the recovery of growth in the second half of the year.
Performance brief On August 23, 2024, the company released its 2024 interim report. In the first half of 2024, the company achieved revenue of 3.448 billion yuan, down 8.4% year-on-year; net income attributable to shareholders was 0.382 billion yuan, down 25% year-on-year.
Full text of the 2024 interim report of Zhejiang Conba Pharmaceutical.
Summary of Zhejiang Conba Pharmaceutical's 2024 semi-annual report
Zhejiang Conba Pharmaceutical (600572.SH): The net income in the first half of the year was 0.382 billion yuan, a decrease of 25.95% year-on-year.
On August 23, Gelon Hui announced the 2024 interim report for Zhejiang Conba Pharmaceutical (600572.SH), with operating revenue of 3.448 billion yuan, a year-on-year decrease of 8.40%; net income attributable to the shareholders of the listed company was 0.382 billion yuan, a year-on-year decrease of 25.95%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.336 billion yuan, a year-on-year decrease of 19.02%; and basic earnings per share was 0.150 yuan. In the first half of 2024, the company firmly implemented the global strategy of focusing on the development of traditional Chinese medicine and the core business of health, actively responding to industry policies and market changes, and continuously promoting the development of major brands.
No Data
No Data